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Background: Recent studies have demonstrated a possible association between
myocardial injury after transfemoral (TF) TAVR and (1) adverse clinical events, and
(2) a decreased improvement in left ventricular ejection fraction (LVEF).
Methods: Patients (pts) from the PARTNER trial (randomized and continued
access cohorts) treated with TF-TAVR who had baseline and 24h cardiac marker
values (cardiac troponin I [cTnI] and/or creatine kinase-MB [CKMB]) were
included in the analysis. Pts were divided into tertiles (T1, T2, T3) based on the
difference between the 24h and the baseline values of each cardiac marker (DcTnI
and DCKMB). Clinical and echocardiographic outcomes were compared between
tertiles.
Results: A total of 546 pts were included in the DcTnI analysis (T1 [-3.76 to 0.29
ng/mL])¼180, T2 [0.30 to 0.85 ng/mL]¼184, T3 [0.88 to 57.96 ng/mL])¼182),
while 629 pts comprised the DCKMB analysis (T1 [-80.0 to 0.8 U/L]¼208, T2 [0.9
to 2.9 U/L]¼213, T3 [3.0 to 85.9 U/L]¼208). At 30 days, patients in the highest
tertile (T3) of cardiac biomarker elevation, as compared with patients in the lowest
tertile (T1), had a statistically higher rate of all-cause mortality (DcTnI: T3: 5.5% vs
T1: 0.6%, p¼0.006; DCKMB: T3: 5.8% vs T1: 1.0%, p¼0.007) and cardiovascular
mortality (DcTnI: T3: 5.0% vs T1: 0.6%, p¼0.011; DCKMB: T3: 3.9% vs T1:
0.5%, p¼0.018). The 30-day rates of myocardial infarction were similar across the
tertiles for both markers (DcTnI: p¼0.3240, DCKMB: p¼0.3594). At 1 year, only
the highest CKMB tertile was statistically associated with higher all-cause
mortality (DcTnI: T3: 23.9% vs T1: 19.8%, p¼0.225; DCKMB: T3: 25.9% vs T1:
17.9%, p¼0.029) (ﬁgure1) and higher cardiovascular mortality (DcTnI: T3: 18.8%
vs T1: 12.3%, p¼0.859; DCKMB: T3: 17.1% vs T1: 10.2%, p¼0.029). After
multivariable analysis, the highest tertiles of cardiac biomarker elevations remained
independent predictors of 30-day and 1 year all-cause mortality. The degree of
myocardial injury did not inﬂuence the improvement of NYHA class (DcTnI:
p¼0.1971, DCKMB: p¼0.2149) or LVEF(DcTnI: p¼0.7187, DCKMB: p¼0.8298)
at 1 year.O
R
A
L
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cardiac enzyme elevations were associated with higher 30-day (cTnI and CKMB)
and 1-year all-cause and cardiovascular mortality (CKMB) rates. The degree of
myocardial injury had no impact on improvement of the NYHA class or recovery of
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Background: The PARTNER trial demonstrated superior survival with transcatheter
aortic valve replacement (TAVR) compared to standard therapy (ST) in inoperable
patients with symptomatic, severe aortic stenosis (AS). We sought to evaluate the
effect of left ventricular (LV) dysfunction on clinical outcomes and the impact of
management approach on LV functional recovery.
Methods: The PARTNER trial cohort B randomized inoperable patients with severe
AS to TAVR or ST. Patients were stratiﬁed by the presence of LV ejection fraction
(LVEF) <50%. Improvement in LVEF was deﬁned as an 10% absolute improve-
ment in LVEF at 30-days.
Results: Left ventricular dysfunction was present in 118 patients (59 TAVR and 59
ST patients). Baseline LV dysfunction was associated with an increased risk of
cardiac mortality at 1-year with ST (HR¼1.71 [95% CI 1.08, 2.71]; P¼0.02) but
not with TAVR. TAVR was associated with survival advantage regardless of
baseline LVEF. Improvement in LVEF occurred in 48.7% and 31.0% of TAVR
and ST patients, respectively (P¼0.16). Smaller LV diastolic dimensions and
higher aortic valve gradients were associated with increased likelihood of LVEF
improvement during ST which in turn was associated with markedly reduced all-
cause mortality rates (HR¼0.32 [95% CI 0.11, 0.93]; P¼0.03). Improvement in
LVEF did not impact outcomes after TAVR. All-cause mortality at 1-year was
similar in those with LVEF improvement during ST and after TAVR (28.6 vs
31.6%; P¼0.84).
Conclusions: In inoperable patients with severe AS, TAVR is associated with
improved survival regardless of baseline LVEF and should be considered the standard
of care for inoperable patients with symptomatic severe AS and LV dysfunction.
Improvement in LVEF during ST portends favorable survival that is similar to that
seen after TAVR in inoperable patients.
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Background: Permanent pacemaker implantation (PPI) is frequently required after
transcatheter aortic valve replacement (TAVR), but limited data is available regarding
predictors and clinical consequences.
Methods: Patients without prior PPI who underwent TAVR in the PARTNER
Trial and randomized continued access registry were included in this analysis.
Multivariable analysis was performed to identify clinical, EKG, and echocar-
diographic (Echo) predictors of PPI after TAVR. Clinical and Echo outcomes
were compared between patients with and without PPI within 30 days of
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